hVIVO (LSE:HVO) reported a challenging 2025, with revenue falling to £46.8 million from £62.7 million and adjusted EBITDA declining to £1.4 million. The downturn reflects a transitional year for the business alongside broader macro pressures across the pharmaceutical services sector. Profitability and cash levels were notably lower, although the company ended the year with a £30 million contracted order book and expects a return to growth in 2026, with revenue forecast to increase by high single digits, weighted toward the second half.
During the year, hVIVO expanded its capabilities through the acquisition and integration of two Clinical Research Units in Germany from CRS, as well as UK-based Cryostore. These additions broaden its offering into early-phase trials, cardiometabolic and immunology studies, and temperature-controlled storage. The group has also reorganised into four core service lines and introduced a validated human metapneumovirus (hMPV) challenge model. Further progress includes securing multi-site trial agreements and an influenza challenge study with Traws Pharma, while unifying its operations under a single hVIVO brand to reflect its evolution into a more diversified clinical development partner.
Management believes the expanded platform and increased cross-selling between its UK and German operations will reduce reliance on infectious disease challenge trials and support margin recovery over time. A strong pipeline across all service lines, combined with ongoing discussions for additional contracts, underpins confidence in long-term growth and a stronger competitive position within the sector.
From an investment standpoint, the outlook reflects a mix of improving fundamentals and lingering challenges. While revenue growth prospects and a relatively low leverage position are supportive, recent financial performance has been weak. Technical indicators show positive momentum, though the share price remains below key moving averages, suggesting potential resistance. Valuation appears attractive, with a low price-to-earnings ratio and a modest dividend yield offering appeal to value-oriented investors.
More about hVIVO plc
hVIVO plc is a UK-based, full-service clinical development company and a global leader in human challenge trials, working with several of the world’s largest biopharmaceutical firms. The group provides an integrated platform covering early-stage development, including preclinical planning, first-in-human studies, Phase II trials, and specialist laboratory services, across facilities in the UK and Germany.
Its four core divisions—Consulting, Clinical Trials, Human Challenge Trials, and Laboratories—are designed to accelerate drug development timelines. hVIVO also operates extensive participant recruitment capabilities, including the FluCamp platform, and runs the world’s largest quarantine facility for controlled human infection studies in London.
Leave a Reply